LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Paper-Based Portable Diagnostic Platform Accurately Detects Mosquito-Borne Diseases Under Field Conditions

By LabMedica International staff writers
Posted on 09 Mar 2022
Print article
Image: A `lab-in-a-box`, the PLUM reader (Portable, Low-cost, User-friendly, Multimode), presents results from up to 384 patient samples and displays them in a single image capture (Photo courtesy of Livia Guo, LSK Technologies)
Image: A `lab-in-a-box`, the PLUM reader (Portable, Low-cost, User-friendly, Multimode), presents results from up to 384 patient samples and displays them in a single image capture (Photo courtesy of Livia Guo, LSK Technologies)

Field trails conducted in Latin America have shown that a paper-based portable diagnostic platform could accurately detect patients with mosquito-borne diseases with sensitivities equivalent to laboratory PCR tests.

In low-resource settings, resilience to infectious disease outbreaks can be hindered by limited access to diagnostic tests. In response to this limitation, investigators at the University of Toronto (Canada) and the biotech company LSK Technologies (Toronto, Canada) developed a portable diagnostic platform that was a combination of a cell-free, paper-based test and a field-ready companion device that allowed data to be collected using image-based color analysis. Called “PLUM” (Portable, Low-cost, User-friendly, Multimode), the conveniently-sized reader presented results from up to 384 samples and displayed them in a single image capture.

In the initial studies, the platform was optimized for detection of first Zika and then chikungunya viruses with reagents that could be freeze-dried, allowing for distribution without refrigeration

Using RNA extracted from the serum of patient samples collected in Brazil, the investigators found that the combined PLUM reader and paper-based Zika sensor provided analytical sensitivity and specificity for the Zika virus equivalent to RT–qPCR (quantitative real-time PCR) with a diagnostic accuracy of 98.5%. The investigators then demonstrated that by simply changing the molecular components that confer specificity to the assay, they could detect the chikungunya virus with 98.5% accuracy.

“We see emerging diagnostics, like the paper-based tests we have developed, as having tremendous near-term potential to augment existing PCR capacity, improve equity in access to health care, and aid in the responses to public health crises,” said senior author Dr. Keith Pardee, assistant professor of pharmaceutical sciences at the University of Toronto.

A sticking point delaying the field use of the PLUM system is that the extraction of RNA from patient samples requires liquid handling by skilled technicians. “With performance on patient samples now validated, we are tackling these next challenges, like sample preparation, so that the platform and PCR-like diagnostic capacity can be distributed more broadly into the communities where they are needed,” said Dr. Pardee.

The Zika virus field test was described in the March 7, 2022, online edition of the journal Nature Biomedical Engineering.

Related Links:
University of Toronto 
LSK Technologies 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.